RGNX Dividend: Regenxbio Inc Yield Insights

RGNX Financial

Regenxbio Inc

$13.59

5.56%

$0.71

As of today:Dec 04, 15:45:59 GMT-5

Income

Balance sheet

Cash flow

Annual

Quarterly

RGNX Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	161	83	90	112	470	154
Revenue Growth (YoY)	92%	-8%	-20%	-76%	204.99%	340%
Cost of Revenue	20	33	37	54	51	35
Gross Profit	140	49	53	58	418	118
Selling, General & Admin	75	71	88	85	79	63
Research & Development	219	208	232	242	181	166
Operating Expenses	295	280	321	321	258	238
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-177	-227	-263	-280	141	-106
Income Tax Expense	--	--	0	0	13	5
Net Income	-177	-227	-263	-280	127	-111
Net Income Growth	-26%	-14%	-6%	-320%	-214%	18%
Shares Outstanding (Diluted)	51.68	49.5	43.73	43.2	43.9	37.3
Shares Change (YoY)	2%	13%	1%	-2%	18%	2%
EPS (Diluted)	-3.44	-4.58	-6.02	-6.5	2.91	-2.98
EPS Growth	-27%	-24%	-7%	-323%	-198%	16%
Free Cash Flow	-106	-175	-228	-238	134	-81
Free Cash Flow Per Share	-2.05	-3.53	-5.21	-5.5	3.05	-2.17
Gross Margin	86.95%	59.03%	58.88%	51.78%	88.93%	76.62%
Operating Margin	-95.65%	-277.1%	-297.77%	-233.92%	34.04%	-77.27%
Profit Margin	-109.93%	-273.49%	-292.22%	-250%	27.02%	-72.07%
Free Cash Flow Margin	-65.83%	-210.84%	-253.33%	-212.5%	28.51%	-52.59%
EBITDA	-139	-214	-251	-250	169	-111
EBITDA Margin	-86.33%	-257.83%	-278.88%	-223.21%	35.95%	-72.07%
D&A For EBITDA	15	16	17	12	9	8
EBIT	-154	-230	-268	-262	160	-119
EBIT Margin	-95.65%	-277.1%	-297.77%	-233.92%	34.04%	-77.27%
Effective Tax Rate	--	--	0%	0%	9.21%	-4.71%